What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “This study is a Phase 1b open-label study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of WU-NK-101 in combination with cetuximab in patients with advanced and/or metastatic CRC (Cohort 1), and in patients with advanced and/or metastatic SCCHN (Cohort 2). The overall study will be comprised of two phases, a Dose Escalation Phase, and a Cohort Expansion Phase.”In the company’s words, NCT05674526 on ClinicalTrials.gov
Other drugs for Colorectal Cancer Metastatic
- DostarlimabGSK · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- GRT-C901Seattle Project Corporation · Phase 2/3
- GRT-R902Seattle Project Corporation · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 30 Sep 2025 | A Phase 1b Study of WU-NK-101 in Combination With Cetuximab | |
| Phase 1Completed | 8 Oct 2024 | A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026